Provider & product review
Breeze Meds NAD+ Review: Three Prices, and No Terms of Service
Breeze Meds names four pharmacies and two NPI-verified doctors, then prices one NAD+ injection three ways — on a site with no refund policy at all.
Our verdict
Breeze Meds may interest someone who values published clinician and pharmacy names, but we would resolve its pricing and refund terms before enrolling. The public NAD+ page gives an injection starting price of $169, a $179 introductory headline and a regular $249/month FAQ figure; the nasal card starts at $210. These do not establish one consistent recurring quote. Ask for the final supply, renewal amount, consultation charge and cancellation policy in writing.
Published names make follow-up questions easier; they do not prove current licensing, product quality or that a particular pharmacy will fill your order. The research discussed below does not establish a cognitive benefit from NAD+ injections or nasal spray.
On this page
What it costs — and the three numbers on one page
The current page shows starting at $169 for injection and starting at $210 for nasal spray, alongside a $179 to start headline and an FAQ regular rate of $249/month. We list the price as conflicting rather than converting an unstated supply period into a monthly rate.
The public price statements are:
- the hero: *"Just $179 to start"*
- the product card: *"Starting at $169 NAD+ Injection"*
- the product card: *"Starting at $210 NAD+ Nasal Spray"*
- the FAQ, further down the same page: *"BreezeMeds NAD+ therapy starts regular at just $249/month, including your medical consultation, prescription, medication, and free shipping"*
One NAD+ injection, three prices, one page
| Where on the page | What it says | States a period? | Corroborated? |
|---|---|---|---|
| Hero | “Just $179 to start” | No | One surface only |
| Product card — injection | “Starting at $169” | No | ✅ Card + catalog agree |
| Product card — nasal spray | “Starting at $210” | No | ✅ Card + catalog agree |
| FAQ, same page | “regular at just $249/month” | ✅ Yes | One surface only |
| Product card — sermorelin | “Starting at $100” | No | Catalog says $135 |
Three different numbers for one product, on one page — and only the $249 states a billing period at all. "Starting at $169" does not say per what.
The sermorelin line does the same thing on a smaller scale: the card says $100, the catalog says $135, and the gap between the two is $35 with nothing on the page to reconcile them.
No one figure reconciles these statements. Ask Breeze for the final recurring amount and supplied period, including whether the introductory amount differs from renewal.
One more, on the weight-loss side, because it shows the same habit: Breeze's GLP-1 "bundles" are worse than paying monthly. The three-month semaglutide bundle is $748, which is $249.33 a month against a $199 month-to-month rate. A bundle that costs more is not a saving, and it should not be read as one.
And if you choose a phone or video consultation and then do not proceed, there is an $80 consultation fee.
The missing legal layer
This is the finding that matters most, and it is very simple to check.
`/terms`, `/terms-of-service`, `/privacy-policy`, `/privacy` and `/refund-policy` all return 404. There is no terms of service. There is no published refund policy, no cancellation policy and no shipping policy. The privacy policy exists only as inline text on the home page — not as a document with a URL you could bookmark, cite or compare against a later version.
For a company that takes recurring card payments for prescription medication, that is not a paperwork gap. It is the absence of the document that says what you are owed when something goes wrong: a wrong dose, a delayed shipment, a charge after canceling, a prescriber declining to prescribe after you have paid. Every other company in our ranking has something here, even when what it says is unfavorable — Shed buries a two-month minimum in section eleven of its terms, which is worth criticizing precisely because there is a section eleven to read.
Breeze also cannot decide what it is called: the inline privacy text says "Breezemeds, LLC, a Delaware corporation" — itself a contradiction, since an LLC is not a corporation — while the consultation footer says "Breezemeds, Inc."
What it is genuinely good at
Four pharmacies, named, with phone numbers. Belmar, Strive, Epiq Scripts and Casa Pharma Rx. Two companies we rank name more — Ageless names seven and Pallas Health names six — and most name none at all.
Two physicians, named, with NPIs. The clinical side runs through Lion MD: Dr. Ana Lisa Carr, MD (NPI 1689841744) and Dr. Kelly Tenbrink, MD (NPI 1346482684). An earlier NPPES check matched those identifiers; that is not current state-license or staff-assignment verification.
Search results have limits. A previous FDA-index search did not identify a warning letter naming Breeze. This is not proof of current regulatory compliance, pharmacy licensing or product safety.
Two routes. The injection and a nasal spray — which matters because the nasal route is a genuine alternative for people who will not inject, and roughly half of what we rank sells only the needle.
What checks out, and what does not exist
Published names, conflicting prices and policy questions
- ✅ Four pharmacies named with phone numbers: Belmar, Strive, Epiq Scripts, Casa Pharma Rx.
- ✅ Two physicians named with NPIs — previously matched in NPPES; current licenses and staff assignment require confirmation.
- An earlier search identified no letter naming Breeze; this is not enforcement clearance or a safety certification.
- No terms of service, no refund policy, no cancellation policy, no shipping policy: /terms, /terms-of-service, /privacy-policy, /privacy and /refund-policy all 404.
- Belmar, one of the four named pharmacies, received an FDA warning letter in March 2023 — and FDA closed it out in October 2023.
- Entity named as “Breezemeds, LLC, a Delaware corporation” in one place and “Breezemeds, Inc.” in another; patient count is 50,000+ on one page and 100,000+ on another.
- Earlier technical observations raised questions about website data handling. Ask for the current privacy policy; these observations do not establish a breach or the security of a clinical system.
One thing about the pharmacies worth stating precisely
Naming your suppliers means a reader can check them, and checking is what naming is for. One of Breeze's four, Belmar, has a record: an FDA warning letter issued 31 March 2023 concerning compounding practices, addressed to "Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy". The FDA closed that letter out in October 2023.5
FDA's closeout says the firm adequately addressed the violations in the earlier letter. It also states that future regulatory action is possible if new violations are observed. A closeout is not a blanket product approval.5
A previous warning-letter search did not identify a letter naming Breeze itself. That limited observation is not a current enforcement clearance or assurance of product safety. The supplier letter discussed above should be considered on its own terms.
Where the clinical bench actually comes from
Breeze identifies CareValidate as its telehealth platform. Shared names or product text across storefronts should not be treated as independent confirmation of licensing or the pharmacy assigned to your prescription. Ask who will prescribe and dispense your order.
None of that makes Breeze fake, and shared infrastructure is normal. What it means practically is that three brands on one backend are one source, not three second opinions — so if you are comparing Breeze against another company and finding the same doctors, the same pharmacies and the same FAQ, that similarity is the platform, not independent agreement.
The claims on its own page that do not stand up
Breeze's NAD+ page publishes efficacy statistics attributed only to "customer surveys" — including "9/10 patients report feeling 10 years younger" — and its results panel renders as broken placeholder counters: "1M % Increase in energy levels", "1 % Improvement in cognitive Function". A number that renders as 1M% is not a number.
Its patient count is inconsistent with itself: "50,000+" on the home page against "100,000+" on the NAD+ page.
And there is a hygiene problem worth naming for a company handling health data: Breeze's client-side configuration ships a Klaviyo private API key and a Supabase URL and key in plaintext to every visitor's browser.
The evidence, which is the same for everyone we rank
Breeze tells patients that "mental clarity and focus often improve by week 3". No trial of either route has ever measured that, or any other timeline.
No rigorous human trial shows that injected or nasal NAD+ improves cognition, focus or energy. In older adults with mild cognitive impairment, oral nicotinamide riboside raised NAD+ levels and did not improve cognition versus placebo1; a second randomized trial in subjective cognitive decline and mild cognitive impairment found no cognitive benefit either2; and the only human data on a parenteral route is a pilot that tracked NAD+ metabolites through a six-hour infusion and measured no cognitive outcome at all3. Our full position is in the NAD+ and brain-fog evidence review.
The compounded preparations Breeze dispenses are also not FDA-approved products, and a compounded drug is not a generic equivalent of an approved one4.
The bottom line
Breeze publishes clinician and pharmacy names, which gives a buyer specific questions to ask. Confirm the prescriber and dispensing pharmacy assigned to your order; names on a page do not establish that arrangement or current licensing.
It also advertises one injection at $169, $179 and $249 on a single page, prices its sermorelin $35 apart from its own catalog, sells GLP-1 bundles that cost more than paying monthly, and publishes no terms of service, no refund policy and no cancellation policy anywhere at all. You can find out exactly who is involved in your prescription, and nothing whatsoever about what you are owed if it goes wrong.
A few gentle questions
How much does Breeze Meds NAD+ cost?
The injection card starts at $169 and nasal card at $210, with no supplied period stated in those figures. The same page also says “Just $179 to start” in its hero and, in its FAQ, that NAD+ therapy “starts regular at just $249/month”. Only that last figure states a billing period at all.
Why does Breeze Meds show three different NAD+ prices?
We do not know, and nothing on the page reconciles them. The hero, the product card and the FAQ each carry a different number for the same injection, and the sermorelin card ($100) is $35 below Breeze's own catalog ($135). What a reader should take from it is that the number in the checkout is the only one that binds, and that the $249 “regular” framing is Breeze's own wording rather than ours.
Does Breeze Meds have a refund policy?
No published one. /terms, /terms-of-service, /privacy-policy, /privacy and /refund-policy all return 404, so there is no terms of service, no refund policy, no cancellation policy and no shipping policy anywhere on the site. The privacy policy exists only as inline text on the home page. For a company taking recurring payments for prescription medication, that is the document that would say what you are owed when something goes wrong, and it does not exist.
Which pharmacies does Breeze Meds use?
It names four, with phone numbers: Belmar, Strive, Epiq Scripts and Casa Pharma Rx. Naming any at all is unusual in this category. One of them, Belmar, received an FDA warning letter issued in March 2023 concerning compounding practices — and the FDA closed that letter out in October 2023.
Does Breeze Meds have an FDA warning letter?
An earlier search did not identify a letter naming Breeze itself. That does not establish current regulatory compliance or safety. The separately identified supplier letter for Drug Depot dba APS Pharmacy received an FDA closeout in October 2023.
Who are Breeze Meds' doctors?
The clinical side runs through Lion MD, and Breeze names Dr. Ana Lisa Carr, MD (NPI 1689841744) and Dr. Kelly Tenbrink, MD (NPI 1346482684). An earlier NPPES check matched those identifiers; that is not current state-license or staff-assignment verification. Note that these are the same two clinicians other brands on the same CareValidate backend publish, so finding them on two sites is the platform rather than independent corroboration.
Are Breeze Meds' GLP-1 bundles cheaper than paying monthly?
No — they cost more. The three-month compounded semaglutide bundle is $748, which works out at $249.33 a month against a $199 month-to-month rate. A bundle priced above the monthly rate is not a saving, whatever it is labeled.
Does Breeze Meds sell a nasal NAD+ spray?
Yes, with a starting $210 nasal card alongside the starting $169 injection card; confirm the supplied period and final recurring price — two routes, where about half the companies we rank sell only the needle. Neither route has a human trial showing a cognitive or energy benefit, which is our position for every provider here including our own top pick.
Where this comes from
- Orr ME, Kotkowski E, Ramirez P, Bair-Kelps D, Liu Q, Brenner C, et al. (2024). A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. 2024;46(1):665-682. https://pubmed.ncbi.nlm.nih.gov/37994989/
- Wu CY, Kupferschmid AC, Chen L, McManus AJ, Kivisäkk P, Galler JA, et al. (2025). Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment. Alzheimers Dement (N Y). 2025;11(1):e70023. https://pubmed.ncbi.nlm.nih.gov/39817194/
- Grant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, et al. (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience. 2019;11:257. https://pubmed.ncbi.nlm.nih.gov/31572171/
- U.S. Food and Drug Administration (2026). Compounding and the FDA: Questions and Answers. FDA, Human Drug Compounding. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- U.S. Food and Drug Administration (2023). Drug Depot, LLC., dba APS Pharmacy / Belmar Pharma Solutions — closeout letter, October 11, 2023 (MARCS-CMS 653740). FDA. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Read on, gently
Shed NAD+ Review: The $144 You Cannot Buy for One Month
Shed prices NAD+ at $144–$169 a month with no prepay ladder — then its terms set a two-month minimum on every program. We read both documents.
ReadHealthRX NAD+ Review: $161 Injection Plan and What Is Included
HealthRX publishes NAD+ prices, injection quantity, and prepay terms. Our review checks the $161 plan, nasal option, refunds, and evidence limits.
ReadPallas Health NAD+ Review: Four-Week Pricing and Care
Pallas NAD+ injection lists $139 initially, then $179 every four weeks. Understand the renewal cadence, annual-plan headline, included care and evidence limits.
ReadStrut Health NAD+ Review: The Page Describes the Wrong Molecule
Strut sells a 500 mg NAD+ injection from $149 and prints the dose — then explains NAD+ as a peptide that signals the pituitary. It isn't one.
ReadRxSpan MD NAD+ Review: Routes, Prices, and Visit Fees
RxSpan MD lists NAD+ injection, nasal spray, and flex-dose tablets. We compare $249/$199 base prices, prepay totals, and the consultation-fee caveat.
ReadAgelessRx NAD+ Review: Intro Pricing, Three Formats and Evidence
AgelessRx NAD+ reviewed: the $79 injection introduction, $149 follow-on rate, nasal and patch options, cancellation and what its research actually shows.
Read